LOTUSEYE

Lotus Eye Hospital and Institute Share Price

 

 

Start SIP in LOTUSEYE

Start SIP

Performance

  • Low
  • ₹126
  • High
  • ₹130
  • 52 Week Low
  • ₹55
  • 52 Week High
  • ₹139
  • Open Price₹128
  • Previous Close₹127
  • Volume32,247

Investment Returns

  • Over 1 Month + 21.36%
  • Over 3 Month + 5.8%
  • Over 6 Month + 81.58%
  • Over 1 Year + 88.79%

Smart Investing Starts Here Start SIP with Lotus Eye Hospital and Institute for Steady Growth!

Invest Now

Lotus Eye Hospital and Institute Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 393.3
  • PEG Ratio
  • -7.5
  • Market Cap Cr
  • 265
  • P/B Ratio
  • 4.4
  • Average True Range
  • 6.45
  • EPS
  • 0.32
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.14
  • RSI
  • 63
  • MFI
  • 72.95

Lotus Eye Hospital and Institute Financials

Lotus Eye Hospital and Institute Technicals

EMA & SMA

Current Price
₹127.43
+ 0.79 (0.62%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹120.63
  • 50 Day
  • ₹116.39
  • 100 Day
  • ₹109.52
  • 200 Day
  • ₹97.96

Resistance and Support

127.74 Pivot Speed
  • R3 134.52
  • R2 132.36
  • R1 129.90
  • S1 125.28
  • S2 123.12
  • S3 120.66

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lotus Eye Hospital And Institute has an operating revenue of Rs. 50.31 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 3% needs improvement, ROE of 1% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 9% and 39% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 8% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 32 which is a POOR score indicating inconsistency in earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 86 indicates it belongs to a poor industry group of Medical-Hospitals and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lotus Eye Hospital and Institute Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results
2025-08-12 Quarterly Results
2025-05-29 Audited Results
2025-02-12 Quarterly Results
2024-11-12 Quarterly Results
Date Purpose Remarks
2022-09-10 FINAL Rs.0.50 per share(5%)Final Dividend
View Lotus Eye Hospital and Institute Dividend History Arrow

Lotus Eye Hospital and Institute F&O

Lotus Eye Hospital and Institute Shareholding Pattern

40.64%
0%
38.7%
20.66%

About Lotus Eye Hospital and Institute

  • NSE Symbol
  • LOTUSEYE
  • BSE Symbol
  • 532998
  • Managing Director
  • Ms. Sangeetha Sundaramoorthy
  • ISIN
  • INE947I01017

Similar Stocks to Lotus Eye Hospital and Institute

Lotus Eye Hospital and Institute FAQs

Lotus Eye Hospital and Institute share price is ₹127 As on 26 December, 2025 | 03:49

The Market Cap of Lotus Eye Hospital and Institute is ₹265 Cr As on 26 December, 2025 | 03:49

The P/E ratio of Lotus Eye Hospital and Institute is 393.3 As on 26 December, 2025 | 03:49

The PB ratio of Lotus Eye Hospital and Institute is 4.4 As on 26 December, 2025 | 03:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23